Vontobel Financial Products GmbH Share Price

Certificat

DE000VU95860

Delayed Deutsche Boerse AG 12:54:46 14/06/2024 BST
85.66 EUR +0.30% Intraday chart for Vontobel Financial Products GmbH
Current month+5.76%
1 month+6.56%
Date Price Change
14/06/24 85.66 +0.30%
13/06/24 85.4 +0.91%
12/06/24 84.63 +0.65%
11/06/24 84.08 +0.66%
10/06/24 83.53 -0.91%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 12:54 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU9586
ISINDE000VU95860
Date issued 21/07/2023
Strike 300 CHF
Maturity 20/09/2024 (98 Days)
Parity 0.3 : 1
Emission price 100
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 102.2
Lowest since issue 76.32
Spread 1
Spread %0.12%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
245.8 CHF
Average target price
278.1 CHF
Spread / Average Target
+13.12%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW